Weill Cornell Medicine researchers received a $1 million PCF Challenge Award to develop an AI model for early detection of treatment-resistant prostate cancer subtypes.
Key Details
- 1Dr. Ekta Khurana leads the project, collaborating with Memorial Sloan Kettering Cancer Center.
- 2The team received a $1 million, two-year Prostate Cancer Foundation Challenge Award.
- 3Research focuses on AI models trained on pathology slides, gene activity, and treatment outcomes.
- 4Project aims to identify patients with tumors likely to develop resistance early so they can be matched to appropriate trials.
- 5Validation of the developed AI model in clinical trials is planned for a follow-on project.
Why It Matters
Developing AI tools to distinguish treatment-resistant tumor subtypes could significantly improve personalized care and trial selection for prostate cancer, addressing a pressing clinical need. Integration of pathology, genomics, and AI in this way is at the forefront of imaging-based precision medicine.
Source
EurekAlert
Related News
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.